New KEYTRUDA Approvals Strengthen Merck's Oncology Portfolio

In late June 2026, Merck & Co. (MRK) secured new regulatory approvals for its flagship immunotherapy KEYTRUDA. The U.S. FDA approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy for first-line treatment of PD-L1-positive advanced triple-negative breast cancer. Additionally, the European Union approved KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. These approvals further entrench KEYTRUDA at the center of Merck's cancer portfolio.

The Product

KEYTRUDA (pembrolizumab) is a PD-1 inhibitor that helps the immune system attack cancer cells. The new indications target hard-to-treat cancers, broadening its use beyond existing approvals.

Pricing and Availability

Merck has not disclosed pricing details, but KEYTRUDA's current annual list price in the U.S. is approximately $150,000 per patient. Reimbursement and access will vary by region.

Competition

KEYTRUDA faces competition from other PD-1 inhibitors like Bristol Myers Squibb's Opdivo and Roche's Tecentriq. However, these approvals may give Merck a competitive edge in breast and bladder cancers.

Potential Impact on Merck

The approvals help diversify KEYTRUDA's revenue streams ahead of expected patent expirations later this decade, potentially mitigating the impact of biosimilar competition.